Published in Rheumatol Int on November 29, 2003
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther (2012) 1.46
New advances in juvenile spondyloarthritis. Nat Rev Rheumatol (2012) 0.85
Update on juvenile spondyloarthritis. Rheum Dis Clin North Am (2013) 0.85
Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences. Biologics (2008) 0.80
Juvenile spondyloarthritis treatment recommendations. Am J Med Sci (2012) 0.79
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis. Arthritis Care Res (Hoboken) (2015) 0.76
A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol (1994) 11.17
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol (1994) 8.61
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med (2002) 6.26
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol (2002) 1.21
Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol (2000) 1.14
The histocompatibility antigen (HL-A 27) and disease. Semin Arthritis Rheum (1975) 1.12
Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J Rheumatol (1998) 1.10
Juvenile-onset spondyloarthropathies. Rheum Dis Clin North Am (1997) 1.06
A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis (2002) 1.03
The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum (1995) 1.02
Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum (1996) 0.97
Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol (1998) 0.88
TNF-alpha antagonists for the treatment of juvenile-onset spondyloarthritides. Clin Exp Rheumatol (2002) 0.88
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med (2012) 3.14
Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum (2005) 2.48
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol (2007) 1.82
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Ann Rheum Dis (2010) 1.51
Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol (2004) 1.51
Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther (2012) 1.46
Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int (2007) 1.44
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum (2010) 1.24
The NEMO mutation creating the most-upstream premature stop codon is hypomorphic because of a reinitiation of translation. Am J Hum Genet (2006) 1.24
Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med (2005) 1.22
Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol (2004) 1.17
Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford) (2012) 1.11
Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum (2004) 1.09
Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clin Immunol (2011) 1.06
Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) (2011) 1.04
Risk factors for severe Muckle-Wells syndrome. Arthritis Rheum (2010) 0.98
Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol (2011) 0.98
Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Arthritis Rheumatol (2014) 0.93
Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr (2002) 0.92
cblE type of homocystinuria due to methionine synthase reductase deficiency: functional correction by minigene expression. Hum Mutat (2005) 0.92
Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. J Rheumatol (2005) 0.91
Cervical spine involvement in patients with juvenile idiopathic arthritis - MRI follow-up study. Pediatr Rheumatol Online J (2014) 0.90
Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept. Arthritis Care Res (Hoboken) (2014) 0.87
Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother (2009) 0.84
Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int (2006) 0.83
Comorbidity profiles among adult patients with juvenile idiopathic arthritis: results of a biologic register. Clin Exp Rheumatol (2013) 0.83
Evidence-based use of methotrexate in children with rheumatic diseases: a consensus statement of the Working Groups Pediatric Rheumatology Germany (AGKJR) and Pediatric Rheumatology Austria. Rheumatol Int (2005) 0.82
Loss of detectability of Charcot-Leyden crystal protein transcripts in blood cells after treatment with dimethyl sulfoxide. J Immunol Methods (2008) 0.82
Fluorescence optical imaging of juvenile arthritis. J Rheumatol (2011) 0.78
Awareness of Fabry disease among rheumatologists--current status and perspectives. Clin Rheumatol (2011) 0.76
Musculoskeletal manifestations and rheumatic symptoms in patients with cystic fibrosis (CF) no observations of CF-specific arthropathy. J Rheumatol (2008) 0.76
[Definition of criteria for high disease activity using the Juvenile Rheumatoid Arthritis Disease Activity Score]. Z Rheumatol (2014) 0.75
[Effectiveness of interleukin-1 inhibiton for mevalonate kinase deficiency]. Z Rheumatol (2014) 0.75
Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past. Rheumatol Int (2011) 0.75
Paediatric rheumatic disease: Biologic therapy and risk of infection in children with JIA. Nat Rev Rheumatol (2012) 0.75
Successful treatment of autoimmune and lymphoproliferative complications of patients with intrinsic B-cell immunodeficiencies with Rituximab. Br J Haematol (2009) 0.75
Response times follow lognormal or gamma distribution in arthritis patients. J Clin Epidemiol (2010) 0.75
[Development of consensus treatment plans for juvenile localized scleroderma]. Z Rheumatol (2014) 0.75